Development of Löffler's endocarditis in FIP1L1-PDGFRalpha-positive hypereosinophilic syndrome despite continuous imatinib mesylate therapy and continuous complete remission

Am J Hematol. 2010 Apr;85(4):296-9. doi: 10.1002/ajh.21635.
No abstract available

Publication types

  • Case Reports
  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adrenal Cortex Hormones / therapeutic use
  • Adult
  • Anticoagulants / therapeutic use
  • Benzamides
  • Drug Therapy, Combination
  • Endocarditis / drug therapy
  • Endocarditis / etiology*
  • Endocarditis / pathology
  • Eosinophils / physiology*
  • Heart / physiopathology*
  • Humans
  • Hypereosinophilic Syndrome / drug therapy*
  • Hypereosinophilic Syndrome / pathology
  • Hypereosinophilic Syndrome / physiopathology
  • Imatinib Mesylate
  • Male
  • Oncogene Proteins, Fusion / metabolism*
  • Piperazines / therapeutic use*
  • Prednisone / therapeutic use
  • Pyrimidines / therapeutic use*
  • Receptor, Platelet-Derived Growth Factor alpha / metabolism*
  • Remission Induction
  • Thrombosis / etiology
  • Treatment Outcome
  • Warfarin / therapeutic use
  • mRNA Cleavage and Polyadenylation Factors / metabolism*

Substances

  • Adrenal Cortex Hormones
  • Anticoagulants
  • Benzamides
  • Oncogene Proteins, Fusion
  • Piperazines
  • Pyrimidines
  • mRNA Cleavage and Polyadenylation Factors
  • Warfarin
  • Imatinib Mesylate
  • FIP1L1-PDGFRA fusion protein, human
  • Receptor, Platelet-Derived Growth Factor alpha
  • Prednisone